Mind Medicine
€5.39
651
+€0.01+0.28% 今天
统计数据
当日最高
5.39
当日最低
5.39
52周最高
-
52周最低
-
成交量
0
平均成交量
-
市值
474.13M
市盈率
-
股息收益率
-
股息
-
即将到来
收益
13Nov预期
预期每股收益
-0.2533972
实际每股收益
N/A
人们还关注
此列表基于关注MMQ.F的Stock Events用户的观察列表。这不是投资建议。
竞争者
这个列表是基于最近市场事件的分析。这不是投资建议。
Compass Pathways
CMPS
市值511.54M
ATAI Life Sciences N.V.
ATAI
市值218.14M
GH Research
GHRS
市值546.3M
Cybin
CYBN
市值194.47M
Revive Therapeutics
RVVTF
市值3.99M
TripAdvisor
TRIP
市值2.01B
Mydecine Innovations
MYCOF
市值649,542
关于
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Show more...
首席执行官
Mr. Robert Barrow
员工
57
国家
CA
ISIN
CA60255C8850
WKN
000A3DR6E